This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B20.9 (HIV disease resulting in unspecified infectious or parasitic disease) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | HIV disease resulting in infectious disease NOS; immunodeficiency virus disease; HIV disease resulting in infectious or parasitic disease NOS |
| C. Adult onset | Likelihood of onset in adulthood: Very high — B20.9 is used when the causative pathogen has not been identified or the specific type of opportunistic infection was not clearly established at the time of coding. Clinically, it reflects a state in which an adult at the AIDS stage has fever, wasting, and clinical evidence of infection but the pathogen has not been identified. |
| 1. History | In the early AIDS era, many opportunistic infections were recorded under the NOS code because of limits in pathogen identification technology. Advances in molecular diagnostics have made detailed coding possible, but the NOS code is still used in resource-limited settings. |
| 2. Causes | Against a background of HIV-induced immunosuppression, various opportunistic infection pathogens are the cause but have not been specified. Reasons for unidentified pathogens include lack of medical resources, delayed ordering of tests, and cultures that became negative after antibiotic treatment had already been given. |
| 3. Genetics | Applies in the same way as the host genetics of B20.7 and B20.8. In unspecified opportunistic infection as well, CCR5 polymorphisms, HLA type, and innate immunity genes influence HIV progression and susceptibility to opportunistic infection. |
| 4. General epidemiology | B20.9 is used relatively often in regions with limited medical resources or low access to diagnostic testing. The proportion of all AIDS deaths attributable to opportunistic infection with unidentified cause is high, especially in Africa. |
| 5. Pathophysiology | HIV causes a global decline in cell-mediated and humoral immunity, damaging infection defense mechanisms at multiple levels. Even when the pathogen is not identified, the mechanism of opportunistic infection is the same as in B20.0-B20.8. |
| 6. Symptoms | Fever of unknown origin, weight loss, night sweats, generalized weakness, chronic diarrhea, and other nonspecific AIDS-related symptoms. A state in which the classic symptoms of a specific opportunistic infection are not identified or overlap, making it difficult to attribute a clear pathogen. |
| 7. Signs | Markedly low CD4, high-grade viremia, weight loss, lymphadenopathy, fever. Various physical abnormalities may accompany, depending on the cause of infection. |
| 8. Screening | When fever or wasting occurs in a person with HIV, perform a broad opportunistic infection screening panel. Apply a guideline-based screening test protocol according to the CD4 count. |
| 9. Diagnosis | Comprehensive opportunistic infection diagnostic panel (blood culture, tuberculosis screening, cryptococcal antigen, CMV DNA, β-D-glucan, imaging studies). Perform the maximum microbiological testing to identify the pathogen. |
| 10. Treatment | Early initiation of ART. When the pathogen is not identified, empirical anti-infective treatment based on the clinical syndrome. Prophylaxis according to the CD4 level. |
| 11. Prognosis | Failure to identify the pathogen can itself make treatment difficult and worsen the prognosis. Many cases can improve with a combination of ART and empirical anti-infective treatment. |
| 12. Prevention | Minimize use of the NOS code through early initiation of ART, CD4-based prophylaxis, and strengthened diagnostic capacity. |
| 13. References | WHO HIV/OI clinical guidelines and 9 others |
ICD-10 code B20.9 is an 'unspecified (NOS, Not Otherwise Specified)' code that covers HIV disease resulting in infectious or parasitic disease whose causative pathogen has not been specified. The existence of this code is inseparable from the development of the history of AIDS opportunistic infection diagnosis.
When AIDS was first recognized in 1981, microbiological diagnostic technology at the time was very limited. Many patients with clinical evidence of fever of unknown origin, weight loss, and immunosuppression received empirical treatment or died without the causative pathogen being identified. In the 1980s and early 1990s, as electron microscopy, special stains, serum antibody tests, and culture techniques were gradually applied to patients with AIDS, PCP, CMV, cryptococcus, MAC, toxoplasma, and others were established as the main AIDS-defining opportunistic infections.
Even so, in settings with scarce medical resources the causative pathogen often could not be identified, and the B20.9 code was used to code such 'uncertain' clinical situations. In regions with poor medical infrastructure such as Africa and Southeast Asia, B20.9 is still used with considerable frequency today. In addition, cases in which cultures become negative after empirical antibiotic treatment, and cases with clinical evidence of opportunistic infection but no identified pathogen, are also coded as B20.9.
Advances in PCR, next-generation sequencing (NGS), and mNGS (metagenomic NGS) technology have greatly improved the ability to identify opportunistic infection pathogens. In particular, mNGS can simultaneously analyze DNA/RNA of diverse pathogens from clinical specimens without culture, making it possible to diagnose rare pathogens that were previously difficult to identify. With this technological progress, the frequency of use of B20.9 is expected to decline gradually, with a shift to more specific codes.
Because B20.9 denotes an HIV-associated infection with an unspecified causative pathogen, in theory any of the opportunistic infection pathogens included in B20.0-B20.8 may be the cause. There are, however, clinical reasons why the pathogen is not identified. First, limited access to diagnostic testing (resource-limited settings, special tests not performed). Second, culture negativity when antibiotics or antifungals had already been given before specimen collection. Third, symptoms partly improved before testing because of a self-limited course. Fourth, a very rare pathogen not detected by general tests. Fifth, clinical symptoms of the opportunistic infection are nonspecific and there is no clue suggesting a specific pathogen.
Common clinical situations coded as B20.9 are as follows. A severely ill patient with AIDS admitted with a fever of unknown origin (FUO) pattern in whom no pathogen is identified despite extensive testing. A patient presenting with chronic diarrhea in whom stool tests are negative. A patient with respiratory symptoms in whom common causes such as Pneumocystis have been excluded but no other cause is identified either. Even in these cases, if opportunistic infection is strongly suspected clinically, empirical treatment is started regardless of pathogen identification.
The genetic background of B20.9 consists of host genes involved in HIV susceptibility and vulnerability to opportunistic infection, and HIV viral genetics. This applies in the same way as described in detail under B20.7 and B20.8. Homozygosity for the CCR5 Δ32 variant provides strong resistance to CCR5-using HIV-1. HLA-B*57:01 and HLA-B*27:05 are associated with long-term HIV suppression, delaying immunosuppression and thereby suppressing the occurrence of opportunistic infection. Conversely, HLA-B*35 is associated with rapid AIDS progression and opportunistic infection.
Even when the pathogen is unspecified, host immune genes influence the course of opportunistic infection. Loss-of-function variants of innate immune signaling pathway genes such as MyD88 and IRAK-4 cause vulnerability to severe bacterial infection, which acts synergistically with HIV immunosuppression. Defects in IL-12/IFN-γ axis genes (IL-12p40, IL-12Rβ1, IFNGR1, IFNGR2, STAT1) are associated with vulnerability to mycobacteria, Salmonella, and others. Such gene polymorphisms may help explain the tendency for recurrent infection without a specific pathogen in patients with HIV.
Accurate epidemiologic statistics for B20.9 are limited because this code reflects clinical situations in which the pathogen was not identified, so the type of opportunistic infection that actually occurred cannot be known. However, there is a clear inverse relationship with diagnostic capacity and medical resources, and it is used relatively more in resource-limited settings.
According to WHO's 2023 report, a considerable share of the 630,000 HIV-related deaths were due to opportunistic infections, but in many low- and middle-income countries patients die without the causative pathogen being identified. The B20.9 coding rate is estimated to be high especially in rural sub-Saharan Africa and resource-limited settings in South Asia. In contrast, in regions with medical infrastructure, the pathogen identification rate is rising and use of B20.9 is declining with the introduction of mNGS and broad PCR panels.
In Korea, the HIV care system and access to medical care are good, so specific opportunistic infection codes (B20.0-B20.8) tend to be used rather than B20.9. However, B20.9 may be used for foreign persons with HIV, cases with very delayed diagnosis, and severely infected patients admitted to the intensive care unit.
The pathophysiology of B20.9 is a multilayered decline in cell-mediated and humoral immunity caused by HIV, and the same mechanisms as in B20.0-B20.8 apply. HIV progressively destroys CD4+ T cells, impairing cell-mediated immunity, and on top of this multilayered immune defects accumulate, including B-cell dysfunction (impaired specific antibody response despite hyperactivation), reduced macrophage function, and NK cell dysfunction.
As immunosuppression becomes more severe, defense against an increasing variety of opportunistic pathogens is lost, and the frequency of infection with multiple pathogens also rises. In such complex clinical situations, it may be difficult to specify a single pathogen. In addition, HIV itself causes chronic systemic immune activation, so fever, weight loss, and wasting can appear even without opportunistic infection, making clinical differentiation from opportunistic infection even more difficult. Immune reconstitution inflammatory syndrome (IRIS) also acts as a mechanism that unmasks previously latent opportunistic infection and can create clinical situations in which the pathogen is unclear.
The clinical symptoms of B20.9 are nonspecific and difficult to distinguish from cases in which the causative opportunistic infection is identified. The main symptoms are as follows. Fever of unknown origin (FUO pattern): Fever of unidentified cause lasting several weeks or more, often with a pattern of relatively low morning temperature and high fever in the afternoon to evening. Night sweats: Night sweats severe enough to soak the bedding are a classic feature of AIDS-related symptoms. Weight loss: Loss of 10% or more of baseline weight within 1 month. Generalized weakness and fatigue: Extreme fatigue severe enough to markedly limit daily activities. Chronic diarrhea: Chronic watery diarrhea in which no pathogen is identified on stool examination. This may be due to HIV enteropathy itself or to opportunistic infection that is difficult to detect. Respiratory symptoms: Cases with mild cough and dyspnea in which no specific pathogen is identified on chest imaging and microbiological testing. Lymphadenopathy: Persistent generalized lymphadenopathy may be due to HIV itself or to various opportunistic infections. These symptoms do not meet the symptom criteria of the classic opportunistic infections that define AIDS, or several symptoms overlap, making attribution to a specific pathogen difficult.
On physical examination, weight loss (wasting state, cachexia), generalized lymphadenopathy (especially cervical, axillary, inguinal), splenomegaly, and hepatomegaly may commonly be found. Skin findings may include HIV-associated skin diseases such as seborrheic dermatitis, exacerbation of psoriasis, and multiple folliculitis. Oral findings may include aphthous ulcers, traces of oral candidiasis, and oral hairy leukoplakia. A 'fever of unknown origin' pattern, in which fever is clearly confirmed but no specific site of infection is found on physical examination, is the typical clinical situation of B20.9.
Laboratory findings may include markedly decreased CD4+ T-cell count (usually <200/μL), high HIV RNA viral load, leukopenia or normal white blood cell count (immunosuppression despite infection), anemia (chronic inflammation, possible bone marrow involvement), hyperproteinemia (polyclonal hypergammaglobulinemia), elevated CRP and ESR, decreased albumin, and elevated LDH. A characteristic of B20.9 is that no specific pathogen is identified even on extensive testing such as blood culture, urine culture, stool culture, cryptococcal antigen, CMV DNA, β-D-glucan, and chest CT.
In situations where B20.9 may apply, a systematic screening approach is needed to maximize pathogen identification. According to the WHO consolidated HIV care guidelines, the following screening tests are performed first in febrile patients at the AIDS stage. Cryptococcal antigen (serum CrAg): highly sensitive first-line screening in febrile patients with CD4 <100/μL. Tuberculosis screening: WHO recommends TB symptom screening (WHO 4-symptom screen) and Xpert MTB/RIF testing for all patients with HIV. Blood culture: to confirm bacterial and fungal bacteremia. Chest X-ray or CT: screening for pulmonary opportunistic infection. β-D-glucan: screening for PCP, candidiasis, and histoplasmosis. Quantitative CMV DNA PCR: screening for CMV end-organ involvement in patients with CD4 <50/μL. If these tests are also negative, consider advanced molecular diagnostics such as metagenomic next-generation sequencing.
Diagnosis of B20.9 is a stepwise process: first confirm HIV infection, then confirm that there is clinical evidence of infection (fever, wasting, symptoms of infection) but no specific pathogen has been identified. First perform a broad opportunistic infection diagnostic panel: blood cultures (2 sets each for bacteria and fungi), cryptococcal antigen (serum and CSF), Xpert MTB/RIF (sputum), PCP PCR (BAL or induced sputum), quantitative CMV DNA PCR (blood), Toxoplasma serum antibody + brain MRI (if headache or neurologic symptoms), direct stool smear, culture, and PCR (if diarrhea), β-D-glucan (fungal screening), and galactomannan (Aspergillus screening).
If no pathogen is identified on these standard tests, attempt histopathologic diagnosis and culture through tissue biopsy (lymph node, bone marrow, liver, etc.). mNGS (metagenomic NGS) can simultaneously analyze a broad range of pathogens from clinical specimens, including unknown pathogens, rare pathogens, and culture-negative pathogens, and is therefore useful for diagnosis when standard tests are negative. Finally, even if no pathogen is identified, if AIDS-related opportunistic infection is strongly suggested clinically, code B20.9 and start empirical treatment.
Even when the pathogen is not identified, starting or resuming ART as soon as possible is the most important treatment. This is because immune recovery by ART is the most powerful treatment against AIDS-related opportunistic infections overall.
Empirical treatment in febrile patients with HIV in whom no pathogen is identified is based on the clinical syndrome and CD4 count. In a febrile patient with CD4 <200/μL and ground-glass opacities on chest CT, start empirical PCP treatment (TMP-SMX). If cryptococcal antigen is negative but high fever and headache are present, consider empirical treatment for tuberculosis. If bacterial sepsis is suspected, give broad-spectrum antibiotics (third-generation cephalosporin or carbapenem class). To cover most opportunistic infections, giving a treatment dose above the TMP-SMX prophylaxis dose is also an option. Evaluate the clinical response within 3-7 days after starting empirical treatment, and continue, modify, or switch to a different empirical treatment.
Because the pathogen is unidentified, targeted anti-infective treatment is not possible for B20.9, so in theory it may have a poorer prognosis than B20.0-B20.8. However, once immune recovery is achieved with ART, many pathogens are suppressed or eliminated naturally by CD4+ T-cell recovery alone, so the prognosis may improve. A report states that 3-month mortality in patients with HIV with unidentified opportunistic infection reaches 15-25% at CD4 below 50/μL. Early ART initiation, empirical treatment, and efforts to identify the pathogen through intensive testing contribute to improved prognosis.
Two approaches are needed to minimize situations coded as B20.9. First, start ART early after HIV infection so that immunosuppression does not progress to the level at which opportunistic infection occurs. Second, strengthen diagnostic capacity to identify the pathogen quickly when opportunistic infection occurs. Prophylaxis according to the CD4 level (TMP-SMX, azithromycin, fluconazole, etc.) prevents the occurrence of major opportunistic infections. In settings with limited access to care, symptom-based empirical preventive treatment can reduce situations corresponding to B20.9. In addition, the spread of advanced diagnostic technologies such as mNGS reduces the frequency of B20.9 coding and enables more accurate coding.
WHO. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. WHO. 2021. ISBN: 9789240031593.
Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. DHHS. 2024. https://clinicalinfo.hiv.gov/
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258-271. DOI: 10.1016/S0140-6736(14)60164-1. PMID: 24907868.
Coffin J, Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med. 2013;3(1):a012526. DOI: 10.1101/cshperspect.a012526. PMID: 23284080.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-1533. DOI: 10.1016/S0140-6736(13)61809-7. PMID: 24152939.
Korenromp EL, Williams BG, de Vlas SJ, et al. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis. 2005;11(9):1410-1419. DOI: 10.3201/eid1109.050337. PMID: 16229771.
Boulware DR, Meya DB, Muzoora C, et al; COAT Trial Team. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498. DOI: 10.1056/NEJMoa1312884. PMID: 24963568.
Walker NF, Scriven J, Meintjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl). 2015;7:49-64. DOI: 10.2147/HIV.S42328. PMID: 25678809.
UNAIDS. Global AIDS Update 2024. UNAIDS. 2024. https://www.unaids.org/
Korea Disease Control and Prevention Agency (KDCA). 2023 HIV/AIDS Notification Annual Report. Korea Disease Control and Prevention Agency. 2024. https://www.kdca.go.kr